Genpact G · NYSE
$37.23 -0.96% (-$0.36)
Summary
71 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- It has raised its dividend 8 years in a row and pays out only 21% of profit.
- It bought back its own shares for $283.0M in the last fiscal year, 4.4% of its market value.
What to watch
- Revenue grew by only 5.1% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 10.9 USD for 1 USD of yearly profit. Over the last five years it was 18.5 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 6.5% a year over 5 years. Over the last 3 years it grew by 5.1% a year. For the next fiscal year analysts expect revenue to grow by 7.0%. Earnings per share grew by 19% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 63 USD
- Sales and administration 22 USD
- Taxes and other 4.0 USD
- Net profit 11 USD
Net profit, industry median (Information Technology Services) 6.0 USD
Out of every 100 USD of revenue, 11 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.5 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, safe- Yield
- 1.95%
- Paid out of profit
- 21%
- Raised in a row
- 8 years
You receive $0.73 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Neutral- Buy 19
- Hold 21
- Sell 0
Today's price within the analysts' price targets
The average target of $38.33 is 3.0% above today's price. 48% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Consumer And Healthcare 100%
By region
- INDIA 59%
- Asia Other Than India 16%
- Americas 14%
- Europe 11%
Consumer And Healthcare brings in 100% of revenue.
Segments in detail